Technology and chronic disease management – Authors' reply

Grants

Funding Acknowledgements

SC has received grants and personal fees from Janssen, Eli Lilly, Novo Nordisk, AstraZeneca, Takeda, and Boehringer Ingelheim. MJD has received personal fees from Novo Nordisk, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca, Janssen, Servier, Mitsubishi Tanabe Pharma Corporation, and Takeda Pharmaceuticals International, and grants from Novo Nordisk, Sanofi-Aventis, Lilly, Boehringer Ingelheim, and Janssen. SH has received personal fees from AstraZeneca and NovoNordisk, and his institution has received fees from Eli Lilly, NovoNordisk, Takeda, and Boeringher Ingelheim for consultancy, speaker panels, and work on advisory boards. SH is chief investigator for a programme grant funded by the UK National Institute for Health Research for the development and trialling of DAFNEplus, a complex intervention to deliver structured education to adults with type 1 diabetes in the UK. JS reports that her institution (the Australian Centre for Behavioural Research in Diabetes) received non-financial support, speaker fees, honoraria (advisory board), and travel support from Roche Diabetes Care (Australia); speaker fees and travel support from AstraZeneca and Roche Diabetes Care (global); grants, non-financial support, honoraria (consultancy and advisory board), and travel support from Sanofi; grants and honoraria (consultancy) from Abbott Diabetes Care; speaker fees from J&J Diabetes Institute and Novo Nordisk; non-financial support, speaker fees, and travel support from Medtronic; and honoraria (advisory board) and travel support from Janssen, outside this work. KK conducted research on the DESMOND structured education programme, which is being rolled out in the UK and elsewhere. FJS declares no competing interests.